{"title":"去甲肾上腺素对重症监护患者压伤的直接影响:回顾性队列研究","authors":"Graziela Argenti, Gerson Ishikawa, Cristina Berger Fadel","doi":"10.1097/ASW.0000000000000027","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To estimate the direct effects of norepinephrine administration on pressure injury (PI) incidence in intensive care patients.</p><p><strong>Methods: </strong>This is a secondary and exploratory analysis of a retrospective cohort study of intensive care patients discharged in 2017 to 2018. Observational cases only included patients who received primary PI preventive care during intensive care (N = 479). As a first-choice vasopressor drug, norepinephrine administration was approximated with days of norepinephrine. Linear path models were examined from norepinephrine administration to PI development. The identification of confounding variables and instrumental variables was grounded on directed acyclic graph theory. Direct effects were estimated with instrumental variables to overcome bias from unobserved variables. As models were re-specified with data analysis, the robustness of path identification was improved by requiring graph invariance with sample split.</p><p><strong>Results: </strong>Norepinephrine caused PI development from one stage to another after 4.0 to 6.3 days of administration in this cohort as a total effect (90% CI). The direct effect was estimated to advance the stage of PI at a rate of 0.140 per day of norepinephrine administered (standard error, 0.029; P < .001). The direct effect accounted for about 70% of the total effect on PI development.</p><p><strong>Conclusions: </strong>Estimations with instrumental variables and structural equation modeling showed that norepinephrine administration directly and substantially affected hospital-acquired PI incidence in intensive care patients in this cohort.</p>","PeriodicalId":7489,"journal":{"name":"Advances in Skin & Wound Care","volume":"36 9","pages":"1-12"},"PeriodicalIF":1.7000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Direct Effects of Norepinephrine Administration on Pressure Injuries in Intensive Care Patients: A Retrospective Cohort Study.\",\"authors\":\"Graziela Argenti, Gerson Ishikawa, Cristina Berger Fadel\",\"doi\":\"10.1097/ASW.0000000000000027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To estimate the direct effects of norepinephrine administration on pressure injury (PI) incidence in intensive care patients.</p><p><strong>Methods: </strong>This is a secondary and exploratory analysis of a retrospective cohort study of intensive care patients discharged in 2017 to 2018. Observational cases only included patients who received primary PI preventive care during intensive care (N = 479). As a first-choice vasopressor drug, norepinephrine administration was approximated with days of norepinephrine. Linear path models were examined from norepinephrine administration to PI development. The identification of confounding variables and instrumental variables was grounded on directed acyclic graph theory. Direct effects were estimated with instrumental variables to overcome bias from unobserved variables. As models were re-specified with data analysis, the robustness of path identification was improved by requiring graph invariance with sample split.</p><p><strong>Results: </strong>Norepinephrine caused PI development from one stage to another after 4.0 to 6.3 days of administration in this cohort as a total effect (90% CI). The direct effect was estimated to advance the stage of PI at a rate of 0.140 per day of norepinephrine administered (standard error, 0.029; P < .001). The direct effect accounted for about 70% of the total effect on PI development.</p><p><strong>Conclusions: </strong>Estimations with instrumental variables and structural equation modeling showed that norepinephrine administration directly and substantially affected hospital-acquired PI incidence in intensive care patients in this cohort.</p>\",\"PeriodicalId\":7489,\"journal\":{\"name\":\"Advances in Skin & Wound Care\",\"volume\":\"36 9\",\"pages\":\"1-12\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Skin & Wound Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/ASW.0000000000000027\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Skin & Wound Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ASW.0000000000000027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的估计去甲肾上腺素给药对重症监护患者压力性损伤(PI)发生率的直接影响:这是对 2017 年至 2018 年出院的重症监护患者进行的一项回顾性队列研究的二次和探索性分析。观察病例仅包括在重症监护期间接受初级 PI 预防护理的患者(N = 479)。作为首选血管加压药物,去甲肾上腺素用药量与去甲肾上腺素用药天数近似。研究了从去甲肾上腺素用药到 PI 发生的线性路径模型。混杂变量和工具变量的确定基于有向无环图理论。利用工具变量估算直接效应,以克服未观察变量带来的偏差。随着数据分析对模型进行重新定义,通过要求图形与样本分割保持不变,提高了路径识别的稳健性:结果:在该队列中,去甲肾上腺素作为总效应(90% CI)导致 PI 在用药 4.0-6.3 天后从一个阶段发展到另一个阶段。据估计,直接效应使 PI 阶段以每施用一天去甲肾上腺素 0.140 的速度提前(标准误差为 0.029;P < .001)。直接效应约占 PI 发展总效应的 70%:结论:利用工具变量和结构方程模型进行的估计表明,去甲肾上腺素的施用直接并显著地影响了该队列中重症监护患者的院内获得性 PI 发生率。
The Direct Effects of Norepinephrine Administration on Pressure Injuries in Intensive Care Patients: A Retrospective Cohort Study.
Objective: To estimate the direct effects of norepinephrine administration on pressure injury (PI) incidence in intensive care patients.
Methods: This is a secondary and exploratory analysis of a retrospective cohort study of intensive care patients discharged in 2017 to 2018. Observational cases only included patients who received primary PI preventive care during intensive care (N = 479). As a first-choice vasopressor drug, norepinephrine administration was approximated with days of norepinephrine. Linear path models were examined from norepinephrine administration to PI development. The identification of confounding variables and instrumental variables was grounded on directed acyclic graph theory. Direct effects were estimated with instrumental variables to overcome bias from unobserved variables. As models were re-specified with data analysis, the robustness of path identification was improved by requiring graph invariance with sample split.
Results: Norepinephrine caused PI development from one stage to another after 4.0 to 6.3 days of administration in this cohort as a total effect (90% CI). The direct effect was estimated to advance the stage of PI at a rate of 0.140 per day of norepinephrine administered (standard error, 0.029; P < .001). The direct effect accounted for about 70% of the total effect on PI development.
Conclusions: Estimations with instrumental variables and structural equation modeling showed that norepinephrine administration directly and substantially affected hospital-acquired PI incidence in intensive care patients in this cohort.
期刊介绍:
A peer-reviewed, multidisciplinary journal, Advances in Skin & Wound Care is highly regarded for its unique balance of cutting-edge original research and practical clinical management articles on wounds and other problems of skin integrity. Each issue features CME/CE for physicians and nurses, the first journal in the field to regularly offer continuing education for both disciplines.